Clinical trials: Unipolar Depression, active
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Major Depression, Major Depression Disorders
Accelerated High-Dose tDCS for Depression
In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression.
- Trial name
- NCT07226011
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder, Bipolar Disorder
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS).
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
- Trial name
- NCT06897670
- Testing
- Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Post-Traumatic Stress Disorder
Imaging SV2A in Mood Disorders
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects.
- Trial name
- NCT02734602
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Major Depressive Disorder
Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool
OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD).
- Trial name
- OPADE (NCT06550037)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Alessio Fasano
Major Depressive Disorder
Mobile Screening for Major Depressive Disorder in Adults From an Ethnically and Socioeconomically Diverse Population.
Major depressive disorder (MDD) is a mental disorder leading to a variety of emotional and physical problems affecting almost 300 million people worldwide.
- Trial name
- MOOD (NCT05989412)
- Testing
- Patient health questionnaire-9 via the Your Research application
- Where
- Netherlands
- Volunteers
- 1,786 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Schizophrenia and Related Disorders, Major Depressive Disorder
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros.
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Trial name
- INTENSIFY (NCT05603104)
- Testing
- Clozapine, Esketamine Nasal Product, Escitalopram
- Where
- Israel
- Volunteers
- 1,254 people
- Sponsor
- Dr. Inge Winter
Major Depressive Disorder, Borderline Personality Disorder
Triage Survey for Psychiatry Research Eligibility
TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.
- Conditions
- Major Depressive Disorder, Borderline Personality Disorder, Generalized Anxiety Disorder
- Trial name
- TRIAGE-Psych (NCT05800925)
- Testing
- Survey
- Where
- 6 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Adams Clinical
Depression - Major Depressive Disorder, Childhood Traumas
Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression
The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult…
- Trial name
- RESPOND (NCT07250893)
- Testing
- Psychotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Depression - Major Depressive Disorder, Anxiety
Comparative Effects of Acceptance and Commitment Therapy, Cognitive Behavioral Therapy, and Treatment-as-Usual on Depression Among People With Marital Crisis
This parallel three-arm, single-blind (assessor-blinded), randomized controlled trial (RCT) aims to compare the effects of ACT, CBT, and treatment-as-usual (TAU) on the severity of depressive symptoms (primary outcome), the…
- Conditions
- Depression - Major Depressive Disorder, Anxiety, Marital Conflict
- Trial name
- NCT07808021
- Testing
- Acceptance and Commitment Therapy, Cognitive Behavioral Therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Universiti Sains Malaysia
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Depression - Major Depressive Disorder, Depression Disorders
Meditative Neurofeedback for Depression
The goal of this study is to test a meditative neurofeedback intervention for depressed mood.
- Trial name
- MediNF (NCT06675240)
- Testing
- MediNF
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Diego
Depression - Major Depressive Disorder, Depression Anxiety Disorder
Evaluating the Effectiveness and Acceptability of a GPT-4o and RAG-Based Voice Chatbot for Depression Screening Using PHQ-9
This study aims to assess the feasibility and acceptability of a voice-based chatbot, powered by GPT-4o and Retrieval-Augmented Generation (RAG), for conducting depression screening using the Patient Health Questionnaire-9…
- Trial name
- GPT4-RAG-PHQ (NCT06801925)
- Testing
- GPT-4o and RAG Voice Chatbot for PHQ-9 Screening
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University College, London
Major Depressive Disorder
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder…
- Trial name
- NCT06223880
- Testing
- AXS-05, Bupropion
- Where
- 40 sites in United States
- Volunteers
- 350 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Lack of perceived control, particularly during stress, has been critically implicated in major depressive disorder (MDD) and anhedonic symptoms, especially among female adolescents; yet the neural underpinnings of perceived…
- Trial name
- NCT04788524
- Testing
- Computer Task Manipulation
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Treatment Resistant Depression, Major Depressive Episode
University of Iowa Interventional Psychiatry Service Patient Registry
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD).
- Conditions
- Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder
- Trial name
- NCT04480918
- Testing
- Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mark Niciu
Anxiety, Depression - Major Depressive Disorder
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.
The study protocol was submitted to ERA-NET NEURON for funding on 28/06/2023. Description of the Israeli responsibilities was extracted from the full submitted research protocol. The protocol includes two studies (CHS1 and CHS2).
- Conditions
- Anxiety, Depression - Major Depressive Disorder, Bipolar, Schizophenia Disorder
- Trial name
- Viral-MI (NCT07453420)
- Where
- Israel
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Major Depression Disorder, Cognitive Deficits
Neuromodulation and Attention Deficits in MDD
Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC)…
- Conditions
- Major Depression Disorder, Cognitive Deficits, Selective Attention
- Trial name
- NCT07111169
- Testing
- intermittent theta burst stimulation (iTBS) intervention
- Where
- China
- Volunteers
- 60 people
- Sponsor
- University of Electronic Science and Technology of China